Journal of International Oncology ›› 2019, Vol. 46 ›› Issue (11): 678-681.doi: 10.3760/cma.j.issn.1673-422X.2019.11.007

Previous Articles     Next Articles

Research advances of EDIL3 in tumor

Ke Bin, Li Bin, Liang Han   

  1. Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy of Tianjin; Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
  • Online:2019-11-08 Published:2019-12-26
  • Contact: Liang Han E-mail:tj_lianghan@126.com
  • Supported by:
     National Natural Science Foundation of China (81401952); Science and Technology Research Project of Tianjin Municipal Health Bureau (2014KZ082)

Abstract: Epidermal growth factor (EGF)-like repeat and discoidin Ⅰ-like domain 3 (EDIL3) is a extracellular matrix  protein that produced and secreted by endothelial cells and plays important roles in embryonic development, angiogenesis, and limit inflammation. Several recent studies indicate that EDIL3 is aberrantly expressed in pancreatic cancer, liver cancer, colorectal cancer, lung cancer and breast cancer, which is associated with cell proliferation, apoptosis, invasion, metastasis, and angiogenesis. EDIL3 is widely participated in the regulating tumor initiation, progression and metastasis, and its abnormal expression is expected to provide a new method for diagnosis and therapy of cancers.

Key words: Neoplasms, Angiogenesis, Apoptosis, EGF-like repeat and discoidin Ⅰ-like domain 3